Deal Watch: First Quarter Posted High Volume, Dollar Value In Alliance Deals
Plus deals involving Cumberland/Apotex, Biogen/TJ Biopharma, Aligos/Amoytop Biotech, Nippon Shinyaku/xFOREST, Oxford BioTherapeutics/Bristol Myers Squibb and more.
Scrip - April 23, 2026

Executives On The Move: Three CEOs, Four CMOs And Five CFOs Among This Week’s Changes
Recent changes in the industry include C-suite changes at Leal Therapeutics, Onco-Innovations and MinervaX, plus Lytix Biopharma gets a new COO from Novo Nordisk.
Scrip - April 23, 2026

Roche Reaffirms Faith In Breast Cancer And Obesity Prospects
But analysts are skeptical about the Swiss firm’s ability to break into key therapy areas where competition will be intense.
Scrip - April 23, 2026

Execs On The Move: April 13–17, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 23, 2026

EU’s PFAS In Supplement Packaging Rules Coming Into Force Soon
Dietary supplement packaging for products sold in the EU must not exceed new limits on per? and polyfluoroalkyl substances set to be introduced from August this year.
HBW Insight - April 23, 2026

Reckitt Weighed Down By Sluggish Cold & Flu Season
Lower incidence of cold & flu in North America and Europe held back Reckitt's Self-Care category performance in Q1. Bright spots for the business included stronger demand for dietary supplements and heartburn brand Gaviscon.
HBW Insight - April 23, 2026

Amneal Joins The Biosimilar A-List With $1bn+ Kashiv Buyout
With a deal worth more than a billion dollars to buy Kashiv BioSciences, Amneal has made it clear that it intends to compete at the highest level in biosimilars. The firm’s leaders set out strategic plans for the future, the value of vertical integration and how Amneal views its closest competitors.
Generics Bulletin - April 23, 2026

Cipla Breaks Ventolin Barrier In US Generics
Cipla has won FDA approval for the first AB-rated generic Ventolin HFA, opening up automatic substitution in a $1.5bn US albuterol inhaler market and expanding its respiratory franchise with planned manufacturing from a new Massachusetts inhalation facility.
Generics Bulletin - April 23, 2026

Ousted Hudson Hailed As Sanofi Enters New Era With CEO Garijo
When Belén Garijo takes the helm at the French drugmaker in the coming days, she will find a company that has just posted a healthy rise in revenues driven, once again, by the immunology blockbuster Dupixent.
Scrip - April 23, 2026

Prestige Biopharma Targets Easier Biosimilar Injections
Prestige Biopharma has patented a gel-forming subcutaneous delivery platform aimed at creating a differentiated version of its trastuzumab biosimilar, potentially improving convenience, dosing and competitiveness in Europe’s crowded oncology biosimilar market.
Generics Bulletin - April 23, 2026

IMDRF AI Framework Could Alter Cost Of Compliance
A new IMDRF draft framework suggests manufacturers of AI-enabled medical devices should implement continuous monitoring, data transparency and performance management through the entire lifecycle of the product.
Medtech Insight - April 23, 2026

AACR: Chinese Firms Present First-In-Class Multispecific ADC, TCE Contenders
Of the China-originated, first-in-class pipeline assets presented at AACR, antibody-drug conjugates and T-cell engagers dominated, with multispecificity a common approach.
Scrip - April 23, 2026